Atea Pharmaceuticals, Inc. financial data

Symbol
AVIR on Nasdaq
Industry
Pharmaceutical Preparations
Location
225 Franklin Street, Suite 2100, Boston, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 6, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.79K % -41.5%
Debt-to-equity 7.5 % +61%
Return On Equity -35.9 % -55.4%
Return On Assets -33.4 % -51.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 85.5M shares +1.62%
Common Stock, Shares, Outstanding 84.5M shares +1.23%
Entity Public Float 253M USD -10.8%
Common Stock, Value, Issued 84K USD +1.21%
Weighted Average Number of Shares Outstanding, Basic 84.3M shares +1.05%
Weighted Average Number of Shares Outstanding, Diluted 84.3M shares +1.05%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 144M USD +26.1%
General and Administrative Expense 48.8M USD -2.14%
Operating Income (Loss) -193M USD -17.5%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -167M USD -24.1%
Income Tax Expense (Benefit) 925K USD -9.14%
Net Income (Loss) Attributable to Parent -168M USD -23.9%
Earnings Per Share, Basic -2 USD/shares -22.7%
Earnings Per Share, Diluted -2 USD/shares -22.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 64.7M USD -55%
Cash, Cash Equivalents, and Short-term Investments 455M USD -21.3%
Assets, Current 462M USD -21.7%
Property, Plant and Equipment, Net 873K USD -32.3%
Operating Lease, Right-of-Use Asset 1.24M USD -32%
Other Assets, Noncurrent 197K USD -85.9%
Assets 465M USD -21.9%
Accounts Payable, Current 4.46M USD +4.85%
Employee-related Liabilities, Current 5.9M USD +3.65%
Liabilities, Current 18.6M USD -42.5%
Accrued Income Taxes, Noncurrent 6.36M USD +10.4%
Operating Lease, Liability, Noncurrent 842K USD -48.7%
Liabilities 25.8M USD -35.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax 233K USD +12.6%
Retained Earnings (Accumulated Deficit) -364M USD -86%
Stockholders' Equity Attributable to Parent 439M USD -21%
Liabilities and Equity 465M USD -21.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -39.9M USD -33.6%
Net Cash Provided by (Used in) Financing Activities 150K USD -9.09%
Net Cash Provided by (Used in) Investing Activities 56.8M USD +132%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 84.5M shares +1.23%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 17.1M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 64.7M USD -55%
Deferred Tax Assets, Valuation Allowance 117M USD +58%
Deferred Tax Assets, Gross 117M USD +58%
Operating Lease, Liability 1.64M USD -31.6%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -168M USD -24.7%
Lessee, Operating Lease, Liability, to be Paid 1.69M USD -32.7%
Property, Plant and Equipment, Gross 1.98M USD 0%
Operating Lease, Liability, Current 800K USD +5.26%
Lessee, Operating Lease, Liability, to be Paid, Year Two 855K USD +2.03%
Lessee, Operating Lease, Liability, to be Paid, Year One 838K USD +2.07%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 51K USD -54.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 855K USD +2.03%
Deferred Tax Assets, Operating Loss Carryforwards 19.5M USD +108%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 6.36M USD +10.4%
Additional Paid in Capital 803M USD +6.93%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 51.8M USD +4.73%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%